January 18, 2024 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company’s annual and general meeting of shareholders held on January 18, 2024 (the “Meeting”). There were 34... Read More

Toronto, Ontario – TheNewswire – December 14, 2023 – Helix BioPharma Corp. (TSX:HBP), (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal... Read More

Toronto, Ontario - TheNewswire - October 27, 2023 - Helix BioPharma Corp. (TSX:HBP) , (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the 2023 fiscal year ended July 31, 2023. OVERVIEW The Company reported a net loss and total comprehensive loss of... Read More

Toronto, Ontario - TheNewswire - October 10, 2023 - Helix BioPharma Corp. (TSX:HBP) (“ Helix ” or the “ Company ”), an immune-oncology antibody-drug-conjugate company developing an innovative drug platform for the treatment of cancer, announced today that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR-NCI-EORTC International Conference on Molecular... Read More

Toronto, Ontario - TheNewswire - August 22, 2023 - Helix BioPharma Corp. (TSX:HBP) (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed the first tranche of private placement financing for gross proceeds of CAD $2,998,000 from the issuance of 16,655,557... Read More

Toronto, Ontario – TheNewswire – June 14, 2023 - Helix BioPharma Corp . (TSX:HBP), (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal 2023 third quarter results for the period ending April 30, 2023. OVERVIEW The Company reported a net loss... Read More

Toronto, ON - TheNewswire - March 15, 2023 - Helix BioPharma Corp. (TSX:HBP) , (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal 2023 second quarter results for the period ending January 31, 2023. OVERVIEW The Company reported a net loss... Read More

Toronto, Ontario – Thenewswire – December 14, 2022 – Helix BioPharma Corp. (TSX:HBP), (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal... Read More

Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced changes in its board of directors (the "Board") and management. The Company is pleased to announce that Mr. Jacek Antas has been appointed as the Company’s CEO to replace Mr. Artur Gabor with... Read More